Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KROS
- Price
- 13.49
- Stock movement up
- +0.94 (6.61%)
- Company name
- Keros Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 616.14M
- Ent value
- 131.89M
- Price/Sales
- 946.44
- Price/Book
- 1.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -67.96%
- 3 year return
- -27.54%
- 5 year return
- -17.03%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KROS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 946.44 |
| Price to Book | 1.16 |
| EV to Sales | 202.59 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 40.62M |
| EPS (TTM) | -5.03 |
| FCF per share (TTM) | -3.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 651.00K |
| Gross profit (TTM) | -179.00K |
| Operating income (TTM) | -204.03M |
| Net income (TTM) | -181.57M |
| EPS (TTM) | -5.03 |
| EPS (1y forward) | -4.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -27.50% |
| Operating margin (TTM) | -31341.63% |
| Profit margin (TTM) | -27890.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 530.68M |
| Net receivables | 1.92M |
| Total current assets | 552.05M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 24.19M |
| Total assets | 579.27M |
| Accounts payable | 4.98M |
| Short/Current long term debt | 19.29M |
| Total current liabilities | 29.01M |
| Total liabilities | 46.44M |
| Shareholder's equity | 532.84M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -140.32M |
| Capital expenditures (TTM) | 2.18M |
| Free cash flow (TTM) | -142.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.08% |
| Return on Assets | -31.34% |
| Return on Invested Capital | -33.96% |
| Cash Return on Invested Capital | -26.65% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 14.14 |
| Daily high | 15.23 |
| Daily low | 14.11 |
| Daily Volume | 1.04M |
| All-time high | 82.74 |
| 1y analyst estimate | 23.00 |
| Beta | 1.33 |
| EPS (TTM) | -5.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Oct 2025 |
Downside potential
Loading...
Downside potential data
| KROS | S&P500 | |
| Current price drop from All-time high | -81.67% | -1.46% |
| Highest price drop | -88.46% | -56.47% |
| Date of highest drop | 1 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -43.52% | -10.99% |
| Avg time to new high | 42 days | 12 days |
| Max time to new high | 1174 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
616.14M
Marketcap category
Small-cap
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Employees
148
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page